Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Another speculation. With all 1.5 million shares sold, we could well be under the £1million balance clause. Which, under the terms would open up RF to give us more cash. The amount would be based on no more than 10% of the market cap and the average 10\20 day trading clause. No option I would like but an option nevertheless.
If a placing is needed and the discount and dilution is big. We need a full explanation, for me, if we don't get a satisfactory explanation, this is the red line where an EGM is called.
As far as i can see, this line hasn't been used until the last RNS. I think the terms are intentionally ambiguous and are being used interchangeably. IMO, there is no reason to put Aug 25 in there, other than spin.
What do you make of the below, MF? This says to me that balances don't need to be paid until Aug next year. I think this line is important.
As announced on 3 August 2023, the Company entered into an Equity Prepayment Facility with RiverFort (the "Facility"). The Company has drawn £2.3 million to date pursuant to the Facility from two prepayment deposits. The Company currently has an outstanding balance of circa £1.3 million under the Facility. Any balances pursuant to the Facility are not due for repayment until August 2025 (the "Maturity Date") and the Company expects to settle all balances by the issuance of Placing Shares prior to the Maturity Date.
I think it is important to point out here that, other than IR answering a question about shareholders contributing to a placing. The company hasn't mentioned a placement or any other type of funding. Also, they are not under any obligation to protect RF which would be illegal and insider trading. It is my belief that Sareum has asked RF to clear down their holding and we won't be giving them more shares until we have to, which is Aug 2025. This should clear the way for SP rises. Yes, there will be some who bought recently that might take profit, including me but essentially we will have to got rid of the ball and chain that is RF, at least until next year. I'm not expecting today to be pretty but the MMs could push the price up a little like they did yesterday. I will buy some more today in anticipation of getting a forward-looking statement with a clear plan to progress. As for what will that cost. I honestly don't know.
The timing of the RNS will depend on the content. If bad new, I may come late tomorrow to protect the sp with a long weekend. If positive, it will come first thing or at 11am. We could get one today but I do think they waiting for RF to offload as many as they can, in fact, Id go as far as saying the board might have asked them to. Hit the bottom and bounce back. Strap in!
The answer is pretty simple, Bull. The financing might not be an immediate problem if the target is to get to the 1a data readout. I think it's obvious that some negotiations are going on. That's why we have complete radio silence. I have been buying in small chunks since last Aug. I bought yesterday and will buy another 2 or 3 tranches this week. This way, if the SP does keep falling, then, I keep averaging down. If I could predict the bottom, I would buy then but as it stands, any piece of good news will see the SP rise and it might 2 or 3 bag in an instant.
I don't know enough about the P1 Study to comment but, I'm not sure Tim can say anything other than topline results. Chances are they won't know how the trial is going\gone until the data is released. for a P1 tox study, no news is good news. For the dosing study, the devil will be in the detail and no one will see that until it's ready to be published. But the fact that the SAD\MAD dosing is continuing should give us hope that P1a is good, how good, who knows?
Topline results just mean results reported factually. It doesn't necessarily mean they are good. It's just Tim using the correct terminology.
What are topline results in clinical studies?
Top-Line Data means, with respect to a clinical study, a summary of patient demographic data, data for the primary endpoint, and safety data derived from the unblinded, locked clinical trial database.
Yes, the only price that is important is your buy and sell price. It might be difficult to get past the loss of big paper profits but it is a lesson learned for most here. I can rationalise the low and falling SP, as you say, it allows us to increase our holdings for very little outlay. What I can't rationalise is the potential dilution that may be needed. If a reason to sack Parker was needed, this is it. I'm hoping that some immediate non-dilutive funding can be found to steady the ship as it were before looking for proper funding for 1b. They could do this with loans linked to options and warrants, maybe from the board or HNWI or Parker. Or, Owens could earn their keep by tapping up their contacts in the industry. We'd still need funding for 1b but if 1a is good, that we shouldn't have a problem.
I bought more yesterday and have some funds to buy more this week but maybe we shouldn't help the MM's\RF out? If the MM's can't fill the orders, the liquidity dries up and the only way to bring it back is to drive the SP up. It feels ridiculous even writing this but a 30p SP would see some here doubling their money.
I agree with your sentiments, Trader Matt. A profit is a profit but if the science is good, then anything less than £10 and the shareholders have been robbed and it's another nail in the coffin for AIM.
I think it's pretty obvious that some sort of negotiation is going on. When they published the interim results RNS last week, they said WC 25th March. I don't think they have done that before, it's usually a date with as BA states, with a presentation notification. I was and I think we all were under the impression that we had enough cash to see us to the end of 1a so the wording of the RNS last week was worrying as it implied we didn't even have enough cash to get to the end of 1a. If so, where has that cash gone? The complete radio silence says to me that we will get an answer to the immediate questions this week and that for me is getting to the 1a data readout. If good then we'll get funding, if not good then, well I don't know but I think this is a squeeky bum time that no one here would've predicted 2 years ago.
Warthog. The all-time high here is a 300 bagger from today's price. It's the AIM dream and, and considering we are much further down the road, it is worth a punt. Is it risky, of course, it is but no riskier than other AIM stock. At least it'll be over quickly for new investors. Not like us, waiting around for 12 years or more.
Yes, maybe, but that's what lawyers are for. If 737 was as good as some here think. Pharma would be kicking the CPF doors in and judging by the deal they announced, they aren't. So at some point and for me it was a while ago, you have to start thinking maybe 737 isn't all it is cracked up to be. However, I still think it's worth £800 million if it goes into combo trials.
It might be cynical but we don't need the drugs to work to make money here, we just need pharma to think they will work.
I think I have a different view of 737 than most here. It is my opinion that the efficacy of 737 in combo isn't as cut and dried as we like to think it is. If it was, Sierra wouldn't have given it away. Nothing to do with Sixth Capital or CPF. phama, including GSK, will have looked at the data and translational studies and they are not convinced yet. It's as simple as that, yes it has potential but someone needs to spend some cash to prove it.